Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal doxorubicin-based therapy in heavily pretreated metastatic breast cancer with brain metastases (retrospective cohort)
ChiCTR2600123758Phase 4Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer and brain metastases, sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Central Nervous System Clinical Benefit Rate (CNS-CBR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR2600123758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123758.